Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male participants aged 18 to 55 years.~2. Body mass index (BMI) 18 to 28 kilograms per meter squared (kg/m\^2) and total body weight \>70 kilograms (kg) (154 pounds \[lb\]).~3. Willingness and ability to comply with the protocol.~4. Vital signs within the normal range.~5. Within 7 days before the first injection, metabolic panel results and complete blood count (CBC) within the laboratory normal reference range.~6. Fasting plasma glucose within the normal range of 90 to 110 milligrams per deciliter (mg/dL) on the morning of the glucose clamp.~7. Agreement not to father a child or donate sperm and to use effective contraception during the study and for at least 30 days after study completion.~8. Willingness and ability to sign an informed consent form.~Exclusion Criteria:~1. Evidence or history of clinically significant hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic (to include history of seizures) or allergic disease, or history of hypoglycemic episodes.~2. Known history of diabetes mellitus.~3. Prior exposure to any insulin or insulin analogs.~4. Known allergy to hyaluronidase or any other ingredient in HYLENEX.~5. Known allergy to bee or vespid venom.~6. Positive urine drug screen results.~7. Positive human immunodeficiency virus (HIV) 1, HIV 2, hepatitis B, or hepatitis C antibody test result.~8. Any history or evidence of alcohol or drug abuse.~9. History or evidence of use of any tobacco- or nicotine-containing product within 6 months of screening, or screening urine nicotine concentration \>50 nanograms per milliliter (ng/mL).~10. Use of prescription or nonprescription drugs within 7 days or 5 half-lives, whichever was shorter, except acetaminophen at doses of less than or equal to 1 gram per day (g/day).~11. Donation of blood in excess of 500 milliliters (mL) within 56 days before dosing.~12. Failure to limit alcohol consumption and refrain from exercise within 48 hours before each injection.~13. Known clinically significant intercurrent illness or other major systemic disease that would unduly risk the participant's safety or interfere with the interpretation of results.~14. Participation in a study of any investigational drug or device 30 days before enrollment in this study.~15. Unfitness for the study, in the investigator's opinion.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Humalog first, then Humalog + rHuPH20 (Type: ACTIVE_COMPARATOR): Humalog first, then Humalog + recombinant human hyaluronidase PH20 (rHuPH20)~A single subcutaneous (SC) injection of 20 units (U) Humalog on Day 1 of the study, followed by a single SC injection of 20 U Humalog + 300 U rHuPH20 after a washout period of at least 6 days
- Humalog + rHuPH20 first, then Humalog (Type: ACTIVE_COMPARATOR): Humalog + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humalog~A single subcutaneous (SC) injection of 20 units (U) Humalog + 300 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humalog after a washout period of at least 6 days
- Humulin-R first, then Humulin-R + rHuPH20 (Type: ACTIVE_COMPARATOR): Humulin-R (recombinant human insulin) first, then Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20)~A single subcutaneous (SC) injection of 20 units (U) Humulin-R on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R + 240 U rHuPH20 after a washout period of at least 6 days
- Humulin-R + rHuPH20 first, then Humulin-R (Type: ACTIVE_COMPARATOR): Humulin-R (recombinant human insulin) + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humulin-R~A single subcutaneous (SC) injection of 20 units (U) Humulin-R + 240 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R after a washout period of at least 6 days

Based on this trial design, predict the completion outcome and termination type (if applicable).